by Mark Chiang

由马克·蒋

Share To

分享到

Mercalis and PharmaCord have officially merged to form a new entity named Valeris. The merger aims to establish a platform designed to improve how life sciences companies deliver their therapies to market. The rebranding marks a significant step in consolidating the expertise and resources of both organizations under one unified brand..

梅尔卡利斯和法玛科德正式合并，组成一个名为瓦莱里斯的新实体。此次合并旨在建立一个平台，旨在改善生命科学公司将其疗法推向市场的方式。品牌重塑标志着在统一品牌下整合两家组织的专业知识和资源迈出了重要一步。

The newly formed Valeris is expected to leverage the combined capabilities of Mercalis and PharmaCord, focusing on streamlining processes for life sciences firms as they navigate the complexities of bringing treatments to patients. Both companies previously operated in areas related to pharmaceutical commercialization and patient support services, and their integration seeks to enhance operational efficiency while addressing industry challenges..

新成立的瓦莱里斯预计将利用梅尔卡利斯和法玛科德的综合能力，专注于为生命科学公司简化流程，帮助它们应对将治疗方法带给患者的复杂性。两家公司此前均在与医药商业化和患者支持服务相关的领域运营，此次整合旨在提高运营效率，同时应对行业挑战。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: May 28, 2025

日期：2025年5月28日

Related posts:

相关内容：

Biopharma’s Shift to Direct Raw Data Platforms Analyzes Extensive Datasets in Real-Time with AI/ML

生物制药转向直接原始数据平台，利用人工智能/机器学习实时分析海量数据集

Generic Drug Approval: Months-Long FDA Review Follows ANDA Filing and Clinical Trials

仿制药批准：ANDA递交和临床试验后需数月的FDA审查

Podcast Highlights Agile Biopharmaceutical Firms’ Strategies for Navigating Complex Clinical Trials

播客亮点：敏捷生物制药公司的复杂临床试验导航策略

WHO Cuts Top Management After U.S. Withdrawal Creates Funding Shortfall

美国退出导致资金短缺，世卫组织削减高层管理人员

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 保留所有权利。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·江

Related Post

相关内容

News Flash

新闻快讯

HHS Ends $600 Million Contract with Moderna for Pandemic Flu Vaccine Development

美国卫生与公众服务部终止了与Moderna价值6亿美元的大流行流感疫苗开发合同

2025-05-28

2025年5月28日